SCHEMBL3570568

SCHEMBL3570568

COc1ccc2c(c1)C(O)(Cc1ccccc1)C(C(=O)O)=C2c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.43
CYP46A1 Q9Y6A2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
EDNRA P25101 3/20 0.39
EDNRB P24530 2/20 0.39
PDK2 Q15119 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GRIN2B Q13224 3/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
MAPK8 P45983 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572579 0.88 PPARG (0.53) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL3572635 0.82 PPARG (0.44) PPARGSMN1; SMN2PDK2ALDH1A1MEN1
SCHEMBL4656348 0.80 PPARG (0.71) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL3580158 0.80 MEN1 (0.43) PPARGSMN1; SMN2EDNRAPDK2ALDH1A1
SCHEMBL3582120 0.76 PPARG (0.53) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL4657622 0.76 PPARG (0.54) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL3570489 0.74 MEN1 (0.39) PPARGSMN1; SMN2PDK2ALDH1A1MEN1
SCHEMBL4654890 0.74 PPARG (0.53) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL3575672 0.74 PPARG (0.57) PPARGSMN1; SMN2ALDH1A1TDP1MEN1
SCHEMBL3572833 0.72 PPARG (0.55) PPARGSMN1; SMN2ALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756036-A4 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2008-04-16 EP claimed
US-20070225288-A1 Indene Derivatives and Process for the Preparation Thereof JEIL PHARM. CO., LTD. (KR) 2007-09-27 US claimed
EP-1756036-A1 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Korea Research Institute of Chemical Technology (KR) 2007-02-28 EP claimed
WO-2005100297-A1 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2005-10-27 WO claimed
US-7745439-B2 Indene derivatives and process for the preparation thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-29 US disclosed
US-7745439-B2 Indene derivatives and process for the preparation thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-29 US disclosed
US-7745439-B2 Indene derivatives and process for the preparation thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-06-29 US disclosed
EP-1756036-A4 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF KOREA RES INST CHEM TECH (KR) 2008-04-16 EP disclosed
US-20070225288-A1 Indene Derivatives and Process for the Preparation Thereof JEIL PHARM. CO., LTD. (KR) 2007-09-27 US disclosed
US-20070225288-A1 Indene Derivatives and Process for the Preparation Thereof JEIL PHARM. CO., LTD. (KR) 2007-09-27 US disclosed
US-20070225288-A1 Indene Derivatives and Process for the Preparation Thereof JEIL PHARM. CO., LTD. (KR) 2007-09-27 US disclosed
EP-1756036-A1 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Korea Research Institute of Chemical Technology (KR) 2007-02-28 EP disclosed
WO-2005100297-A1 INDENE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225288-A1 Indene Derivatives and Process for the Preparation Thereof INSR, GPR119, PPARA PPARG 8/4885CYP46A1 24/4885SMN1; SMN2 4036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.